Should I Buy ADIL? ADIL 2026 Analysis

Should You Buy Adial Pharmaceuticals Inc (ADIL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.210

1 Day change

-2.73%

52 Week Range

1.300

Analysis Updated At

2026/01/28

ADIL is not a good buy right now for a beginner long-term investor with $50k–$100k. The stock is a micro-cap biotech with no revenue, worsening losses/EPS in the latest quarter, no recent news catalysts, and no proprietary buy signals today. Even though momentum is slightly improving short-term, the broader trend remains bearish, making this an unattractive long-term entry at this time.

Technical Analysis

Pre-market price is ~0.2317, sitting just above the pivot support area (Pivot 0.227; S1 0.213) and below near-term resistance (R1 0.24). Trend & momentum: - Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating the larger trend is still down. - MACD histogram is positive (0.00285) and expanding, suggesting a short-term momentum uptick/bounce attempt. - RSI(6) ~47.8 is neutral, implying no strong overbought/oversold edge. Key levels: - Support: 0.227 (pivot), then 0.213 (S1), 0.205 (S2) - Resistance: 0.24 (R1), then 0.248 (R2) Pattern-based odds provided: ~50% chance of a ~5.25% move next day, but only modest projected moves over 1 week/month, which does not compensate for the weak longer-term trend. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Positive Catalysts

- MACD turning positive and expanding suggests short-term momentum improvement (possible technical bounce).
- Price is near pivot/support (0.227), which can sometimes attract short-term dip buyers.
- Hedge funds/insiders show neutral activity (no additional selling pressure indicated by the provided trend summary).

Neutral/Negative Catalysts

- No news in the recent week, so there are no visible event-driven catalysts to re-rate the stock upward.
- Bearish moving-average stack (SMA_200 > SMA_20 > SMA_5) signals an ongoing downtrend.
- Company fundamentals remain weak: no revenue and losses are worsening year-over-year.
- No Intellectia buy signals today (neither AI Stock Picker nor SwingMax), reducing conviction for an immediate entry.
- Congress/politician activity: no recent data available (no sentiment signal from influential buying).

Financial Performance

Latest reported quarter: 2025/Q3. Revenue remained 0 (no meaningful operating revenue). Net income fell to -1,793,651 (down 18.17% YoY), and EPS dropped to -0.08 (down 78.95% YoY). Overall, the latest quarter shows worsening profitability with no growth engine evident from revenue, which is a poor setup for a long-term beginner-focused investment.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating trend or price target change data was provided, so there is no observable recent Wall Street sentiment shift to support a confident long-term buy thesis. Pros view: insufficient/unknown. Cons view: absent coverage/updates typically aligns with lower institutional attention and higher uncertainty for long-term investors.

1 Analyst Rating

Wall Street analysts forecast ADIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADIL is 1.5 USD with a low forecast of 1.5 USD and a high forecast of 1.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.220

Low

1.5

Averages

1.5

High

1.5

Current: 0.220

Low

1.5

Averages

1.5

High

1.5

Maxim

Hold

Buy

upgrade

$1.50

AI Analysis

2025-09-30

Reason